Head to Head Analysis: Ainos (NASDAQ:AIMD) vs. Korro Bio (NASDAQ:KRRO)

Ainos (NASDAQ:AIMD) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Volatility and Risk

Ainos has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ainos and Korro Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$20,000.00	778.22	-$14.86 million	($4.99)	-0.67
Korro Bio	$2.27 million	79.17	-$83.58 million	($9.75)	-1.96

Ainos has higher earnings, but lower revenue than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ainos and Korro Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	-108.25%	-56.94%
Korro Bio	N/A	-61.51%	-42.87%

Analyst Recommendations

This is a summary of recent recommendations for Ainos and Korro Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0	0	0	0	0.00
Korro Bio	0	0	5	2	3.29

Korro Bio has a consensus price target of $86.8333, indicating a potential upside of 353.67%. Given Korro Bio’s stronger consensus rating and higher possible upside, analysts plainly believe Korro Bio is more favorable than Ainos.

Insider and Institutional Ownership

13.2% of Korro Bio shares are owned by institutional investors. 10.4% of Ainos shares are owned by insiders. Comparatively, 4.6% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Korro Bio beats Ainos on 9 of the 14 factors compared between the two stocks.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.